Stock screener

LIXT

Conviction 72HealthcareScan · Thu, Jun 25, 2026
Three outside down
LIXT$6.67-2.98%
ResistanceSupportVol 14
63 bars
Vol MA14 458.82K
Mar 26Apr 14May 1May 19Jun 8Jun 25
LIXTE BIOTECHNOLOGY HOLDINGS, INC.PHARMACEUTICAL PREPARATIONSwww.lixte.com
Price6.67
Change-2.98%
Gap-1.82%
Rel volume0.45×
Avg volume404.93K
Avg $ vol2.83M
SMA 206.88
SMA 505.42
SMA 2004.26
Price vs 50+23.06%
Price vs 200+56.56%
MA stackbullish
50/200 cross
Supertrendup · 5.08
RSI (14)53
MACD hist-0.10
MACD cross
Stoch %K / %D41 / 56
ADX (14)24
+DI / −DI18 / 16
RSI divergenceBearish
MACD divergenceBearish
ATR %+10.81%
ADR %11.18%
52w high7.61
52w low0.7146
From 52w high-12.42%
Above 52w low+832.69%
New 52w highNo
SqueezeOn · 2d
Bollinger width23.25%
%B0.37
Donchian pos43.69%
Donchian high7.78
Donchian low5.80
AVWAP (52w high)7.28
vs AVWAP high-8.44%
AVWAP (52w low)3.04
vs AVWAP low+119.14%
OBV trendFlat
Chaikin MF (20)0.16
Today vs 20d0.45×
Avg vol (14d)458.82K
Avg vol (20d)404.93K
Avg $ vol (20d)2.83M
Market cap82.53M
RS 3m (vs SPY)+142.19%
RS 6m (vs SPY)+51.29%
RS line new highNo
Trend template6/8
Technical rank85.3
1 week-4.24%
1 month+17.96%
3 months+122.91%
6 months+59.83%
1 year+666.97%
YTD+73.57%
P/E-13.58
P/B10.39
P/S412.66
P/FCF
EPS-1.26
Div yield
ROE-76.51%
ROA-55.95%
Debt/Eq
Current2.78
EV/EBITDA
Gross margin
Net margin
Rev growth
EPS growth-69.51%
Price target
Target upside
Analyst rating
Institutional
Ent. value79.12M
Revenue0
Net income-1.98M
Gross profit
Free cash flow
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out15.02M
Employees3
ListedWed, Sep 5, 2007
Free float11.61M
Float %99.9%
Short interest246.97K
Days to cover2.2d
Short volume43.3%
Squeeze score17 / 100
Next earningsThu, Aug 6, 2026 (42d)
EPS forecast
Last EPS vs est
Last surprise
Setup gradeB
Conviction72 / 100
Pattern quality
Tech rank85.3 / 100
Group rank50 / 100
Status lane
Setup direction
Pattern family
Resistance
Support
Days since event
Candle confirmThree outside down
News sentiment

Financials as of Tue, Sep 30, 2025 · quarterly.

Congress activity

Disclosed STOCK Act trades in LIXT

All disclosures →
No recent disclosed trades by Congress in LIXT. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in LIXT · 5 buys · 5 sells

InsiderSideShares
Porter Stuart D
Director · Common Stock · 2026-05-29
Grant25K
Holloway Michael Andrew
Director · Options to Purchase Common Stock · 2026-04-15
Disposition25K
Pursglove Geordan Garrett
CEO and Chairman of the Board · Common Stock · 2026-04-15
Grant350K
Felix Lourdes
Director · Stock Option (right to buy) · 2026-04-15
Disposition25K
Pursglove Geordan Garrett
CEO and Chairman of the Board · Options to Purchase Common Stock · 2026-04-15
Disposition350K
Primus Guy Warren
Director · Common Stock · 2026-04-15
Grant25K
Stazzone Peter
Chief Financial Officer · Options to Purchase Common Stock · 2026-04-15
Disposition50K
Sawyer Jason David
Director · Common Stock · 2026-04-15
Grant25K
Holloway Michael Andrew
Director · Common Stock · 2026-04-15
Grant25K
Primus Guy Warren
Director · Stock Option (right to buy) · 2026-04-15
Disposition25K

SEC filings

EDGAR filings in LIXT · 6 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.